证券代码：688277 证券简称：天智航 公告编号：2023-053 北京天智航医疗科技股份有限公司 关于会计估计变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会计估计变更自北京天智航医疗科技股份有限公司（以下简称"公 司"）第五届董事会第二十四次会议审议通过后，自 2023 年 8 月 1 日起执行。 本次会计估计变更是公司采用未来适用法进行会计处理，无需对已披露 的财务报告进行追溯调整，对公司以往各年度财务状况和经营成果不会产生 影响。 经财务部门初步测算，本次会计估计变更后，预计 2023 年研发支出资本 化约 832.15 万元，利润总额增加约 832.15 万元。以上数据仅为公司财务部 门的初步测算数据，最终数据以经年审会计师审计后的 2023 年度财务报告 为准。 经过长期的研发投入和技术积累，公司研发项目的可行性不断提高，公 司本次会计估计变更的资本化时点为：需要临床试验的研发项目，以医院伦 理会通过，并取得伦理批件时间为资本化时点；不需要临床试验的研发项目， 以第三方检测机 ...

独立董事提名人声明 提名人张送根，现提名徐扬为北京天智航医疗科技股份有限 公司第六届董事会独立董事候选人，并已充分了解被提名人职业 专长、教育背景、工作经历、兼任职务等情况。被提名人已书面 同意出任北京天智航医疗科技股份有限公司第六届董事会独立 董事候选人（参见该独立董事候选人声明）。提名人认为，被提 名人具备独立董事任职资格，与北京天智航医疗科技股份有限公 司之间不存在任何影响其独立性的关系，具体声明如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、规章及其他规范性文件，具有五年以上法律、经济、 财务、管理或者其他履行独立董事职责所必需的工作经验，并已 根据《上市公司高级管理人员培训工作指引》及相关规定取得独 立董事资格证书。 二、被提名人任职资格符合下列法律、行政法规和部门规章 的要求： （一）《公司法》关于董事任职资格的规定； （二）《公务员法》关于公务员兼任职务的规定； （三）中央纪委、中央组织部《关于规范中管干部辞去公职 或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定； （四）中央纪委、教育部、监察部《关于加强高等学校反腐 倡廉建设的意见》关于高 ...

证券代码：688277 证券简称：天智航 公告编号：2023-054 北京天智航医疗科技股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年第二次临时股东大会 召开日期时间：2023 年 9 月 7 日 14 点 00 分 召开地点：北京市海淀区永泰庄北路 1 号中关村东升国际科学园 2 号楼 B1 层会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 7 日 至 2023 年 9 月 7 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2023年9月7日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会 ...

证券代码：688277 证券简称：天智航 公告编号：2023-051 北京天智航医疗科技股份有限公司 关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京天智航医疗科技股份有限公司（以下简称"公司"）第五届董事会任期 即将届满，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上 海证券交易所科创板股票上市规则》以及《公司章程》等有关规定，公司于 2023 年 8 月 22 日召开第五届董事会第二十四次会议，审议通过了《关于选举第六届 董事会非独立董事的议案》《关于选举第六届董事会独立董事的议案》，具体情 况如下： 一、董事会换届选举情况 根据《公司章程》规定，公司第六届董事会由 9 名董事组成，其中独立董事 3 名，非独立董事 6 名。经公司第五届董事会提名委员会资格审查，董事会同意 提名张送根先生、徐进先生、王彬彬女士、马敏先生、朱德权先生、肖治先生为 第六届董事会非独立董事候选人；提名李志勇先生、徐扬先生、张瑞君女士为第 六届董事会独立董事候选人（简历详见附件）。公司第六届董事会董事 ...

独立董事候选人声明 本人李志勇，已充分了解并同意由提名人张送根提名为北京 天智航医疗科技股份有限公司第六届董事会独立董事候选人。本 人公开声明，本人具备独立董事任职资格，保证不存在任何影响 本人担任北京天智航医疗科技股份有限公司独立董事独立性的 关系，具体声明如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、部门规章及其他规范性文件，具有五年以上法律、经济、 财务、管理或者其他履行独立董事职责所必需的工作经验，并已 根据《上市公司高级管理人员培训工作指引》及相关规定取得独 立董事资格证书。 二、本人任职资格符合下列法律、行政法规和部门规章的要 求： （一）《公司法》关于董事任职资格的规定； （二）《公务员法》关于公务员兼任职务的规定； （三）中央纪委、中央组织部《关于规范中管干部辞去公职 或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定； （四）中央纪委、教育部、监察部《关于加强高等学校反腐 倡廉建设的意见》关于高校领导班子成员兼任职务的规定； （五）中国保监会《保险公司独立董事管理暂行办法》的规 定； （六）其他法律、行政法规和部门规章规定的情形。 （七）最近 ...

关于参加 2022 年度医疗设备专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688277 证券简称：天智航 公告编号：2023-038 北京天智航医疗科技股份有限公司 （三）视频和线上文字互动平台：上海证券交易所上证路演中心 （http://roadshow.sseinfo.com/） （四）投资者可于 2023 年 6 月 15 日（星期四）16:00 前通过邮件、电话等 形式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者 普遍关注的问题进行回答。 三、参加人员 参加本次业绩说明会的人员有：公司总经理徐进先生、财务总监齐敏女士、 董事会秘书黄军辉先生（如有特殊情况，参会人员可能进行调整）。 四、联系人及咨询办法 北京天智航医疗科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日发布《公司 2022 年年度报告》，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况、发展理念，公司参与了由上交所主办的 2022 ...

Financial Performance - The company reported a revenue of 156.19 million yuan for the year 2022, with a net loss attributable to shareholders of 110.58 million yuan[4]. - The net profit excluding non-recurring gains and losses was a loss of 133.45 million yuan[4]. - The company has not yet achieved profitability since its listing, which was under the Shanghai Stock Exchange's Sci-Tech Innovation Board standards[4]. - The company's operating revenue for 2022 was CNY 156,188,437.41, a slight increase of 0.11% compared to CNY 156,021,920.91 in 2021[21]. - The net profit attributable to shareholders of the listed company was a loss of CNY 133,454,105.70, which represents an increase in loss of 29.25% compared to a loss of CNY 103,219,039.37 in 2021[21]. - Basic earnings per share for 2022 was a loss of CNY 0.26, which is a 36.84% increase in loss compared to a loss of CNY 0.19 in 2021[22]. - The net cash flow from operating activities for 2022 was a negative CNY 87,506,239.40, compared to a negative CNY 77,755,219.56 in 2021[21]. - The net profit for 2022 was a loss of CNY 112.34 million, an increase in loss of 35.92% year-on-year[34]. - The company reported a significant decrease in costs for supporting equipment and consumables, with a direct cost of 746.61 million, down 40.22% from the previous year's 1,249.00 million[99]. - The company will not distribute profits for the year 2022 due to negative retained earnings as of December 31, 2022[171]. Research and Development - The company increased its R&D investment to 78.52% of operating revenue, up from 70.37% in 2021, reflecting a growth of 8.15 percentage points[22]. - The company's R&D investment reached CNY 122.64 million in 2022, an increase of 11.70% year-on-year[37]. - The company submitted 90 new patent applications during the reporting period, including 37 invention patent applications[37]. - The company has established a comprehensive R&D system that includes cutting-edge technology research, advanced product pre-research, and product development, collaborating with universities, research institutions, and hospitals[46]. - The company aims to integrate new technologies such as 5G communication, 3D printing, smart materials, big data, artificial intelligence, and virtual/augmented reality into its surgical robots, enhancing their intelligence and interaction capabilities[50]. - The company has developed high-precision online calibration technology for its surgical robots, ensuring positioning errors within 0.5 mm, which is critical for surgical safety and accuracy[52]. - The company has created algorithms for multi-modal medical image preprocessing and fusion, allowing for pixel-level precision in integrating preoperative and intraoperative images[54]. - The company employs artificial intelligence algorithms for automatic feature recognition in medical imaging, achieving an error of less than 1 pixel, which enhances surgical accuracy and efficiency[55]. - The company has developed a modular design technology for surgical tools, allowing the orthopedic surgical robot to adapt to various surgical requirements and expand its operational capabilities[57]. - The company has completed the iterative development of three generations of orthopedic surgical robots, enhancing clinical advantages such as precision and minimally invasive procedures[75]. Market and Competition - The orthopedic surgical robot market is still in its early clinical application phase, with increasing awareness among hospitals, doctors, and patients[4]. - The company aims to expand its market share and accelerate the implementation of application scenarios while focusing on technological innovation[4]. - The company is positioned as a leading player in the domestic orthopedic surgical robot market, with increasing competition from new entrants in the industry[49]. - The market for surgical robots is expected to expand rapidly, with a growing recognition and acceptance among doctors and patients, leading to a broader customer base beyond first and second-tier cities[50]. - The company is experiencing intensified competition from major multinational medical device companies, which may threaten its market share and profitability[84]. Operational Efficiency - Sales expenses rose by CNY 19,979,000, a year-on-year increase of 27.97%, due to increased market investment and marketing team development[23]. - The company has implemented a diversified revenue structure, transitioning from single device sales to include ongoing medical technology service income[43]. - The company has established a collaborative innovation mechanism in the medical robotics field, enhancing its continuous innovation capabilities[37]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder interests[136]. - The company has effectively managed its subsidiaries, improving overall operational efficiency and risk resistance[177]. Employee and Management - The company has a total of 362 employees, with 104 holding doctoral or master's degrees, and 128 dedicated to research and development, representing 35.36% of the workforce[78]. - The average salary of R&D personnel rose to 57.54 million, compared to 54.37 million in the previous year[74]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 198.37 million RMB[152]. - The total remuneration for core technical personnel at the end of the reporting period was 95.31 million RMB[153]. - The company has a strict compensation policy based on annual operating performance and industry income levels, ensuring competitive salaries[168]. - The management team emphasizes performance-based remuneration linked to financial and operational metrics[152]. Strategic Initiatives - The company plans to continue focusing on the orthopedic surgical robot business and increase investment in new technologies and products[23]. - The company is actively pursuing international certification for its products, aiming to enhance its market presence globally[72]. - The company is exploring partnerships with key industry players to enhance its competitive edge and drive growth[144]. - A strategic acquisition is in the pipeline, aimed at enhancing the company's technological capabilities and expanding its product portfolio[144]. - The company is focused on building a marketing system that integrates equipment sales, consumable sales, and operational services for orthopedic robots[131]. Environmental and Social Responsibility - The company emphasizes ESG management, focusing on environmental protection and sustainable operations[179]. - The company is not classified as a key pollutant discharge unit and has not faced any administrative penalties for environmental issues during the reporting period[181]. - The company actively implements energy-saving measures and promotes the use of electric vehicles for administrative purposes to reduce carbon emissions[187]. - The company donated 300,000 yuan to the Hainan Shanglin Sunshine Medical Development Foundation in 2022[189].

一、 主要财务数据 2023 年第一季度报告 证券代码：688277 证券简称：天智航 北京天智航医疗科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 | | --- | --- | --- | | | | 年同期增减变 | | | | 动幅度(%) | | 营业收入 | 39,503,426.05 | 130.28 | | 归属于上市公司股东的净利润 | 8,639,060.96 | 不适用 | | 归属于上市公司股东的扣除非经常 | -39,601,959.97 | 不适用 | ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥23,319,659.79, a decrease of 17.89% compared to the same period last year[5] - The net profit attributable to shareholders was -¥38,163,337.19, with a year-to-date loss of -¥82,341,843.73, indicating a significant decline in profitability[5] - The basic earnings per share for the quarter was -¥0.09, reflecting a 50% increase in losses compared to the same period last year[11] - Net profit for Q3 2022 was a loss of CNY 87,757,969.44, compared to a loss of CNY 64,196,247.39 in Q3 2021, indicating a worsening financial performance[20] - The net loss attributable to shareholders of the parent company for Q3 2022 was CNY 82,341,843.73, compared to a loss of CNY 63,764,563.64 in Q3 2021[21] - The comprehensive income total for Q3 2022 was a loss of CNY 86,961,665.96, compared to a loss of CNY 62,180,881.96 in Q3 2021[21] - Basic and diluted earnings per share for Q3 2022 were both CNY -0.20, compared to CNY -0.15 in Q3 2021[21] Research and Development - Research and development expenses totaled ¥28,693,662.73 for the quarter, representing a 23.75% increase year-on-year[6] - The ratio of R&D expenses to operating revenue was 123.04%, an increase of 41.39 percentage points compared to the previous year[6] - Research and development expenses for Q3 2022 were CNY 80,328,845.46, an increase of 15% from CNY 69,879,548.32 in Q3 2021, reflecting a focus on innovation[20] - The company experienced a 52.30% increase in net loss attributable to shareholders compared to the same period last year, primarily due to increased R&D expenses and decreased other income[10] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,210,246,612.90, down 5.38% from the end of the previous year[6] - As of September 30, 2022, the total assets of the company amounted to RMB 1,210,246,612.90, a decrease from RMB 1,279,050,151.42 at the end of 2021, reflecting a decline of approximately 5.4%[15] - The total liabilities as of Q3 2022 amounted to CNY 229,640,842.06, up from CNY 211,482,714.62 in Q3 2021[20] - The total current liabilities decreased to RMB 108,878,839.06 from RMB 113,226,037.45, indicating a reduction of about 3.1%[16] - The total equity attributable to shareholders of the parent company decreased to CNY 925,401,691.42 from CNY 1,006,947,231.67 in the previous year[20] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥129,972,334.28, with significant fluctuations due to changes in cash receipts and payments[11] - The cash flow from operating activities for the first three quarters of 2022 was CNY 86,627,082.28, an increase from CNY 82,547,196.15 in the same period of 2021[24] - The net cash flow from operating activities was -129,972,334.28, compared to -82,650,277.44 in the previous year, indicating a decline in operational cash flow[25] - The total cash outflow from operating activities was 248,997,354.83, compared to 236,161,051.02 in the previous year, indicating increased operational expenses[25] - The cash and cash equivalents at the end of the period were 168,038,447.01, down from 416,628,498.93 year-over-year[26] Shareholder Information - The company reported a total of 16,440 common shareholders at the end of the reporting period[12] - The top shareholder, Zhang Songgen, holds 75,664,000 shares, representing 18.02% of the total shares[12] Inventory and Investments - The inventory increased to RMB 48,727,695.02 from RMB 37,944,429.67, representing an increase of about 28.5% year-over-year[15] - The long-term equity investments increased to RMB 24,833,837.00 from RMB 19,995,742.59, reflecting a growth of approximately 24.1%[16] - The company reported a total of RMB 76,504,550.48 in trading financial assets, down from RMB 120,628,447.13, a decrease of about 36.5%[15] - Cash inflow from recovering investments was 226,045,467.80, down from 428,670,218.84 year-over-year, indicating a decline in investment recovery[25] Operational Highlights - The company has performed over 30,000 surgeries using its orthopedic surgical robots as of the end of the reporting period, marking a significant increase from the previous year[14] - The company has successfully implemented multiple installations of its "purchase technology services" model by the end of the reporting period[14]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥60,945,385.32, a decrease of 20.23% compared to ¥76,396,611.44 in the same period last year[16]. - The net profit attributable to shareholders for the first half of 2022 was -¥44,178,506.54, compared to -¥38,706,806.56 in the previous year[16]. - The net cash flow from operating activities decreased by 51.19% to -¥83,135,564.89, down from -¥54,986,153.02 in the same period last year[17]. - The company's total assets as of the end of the reporting period were ¥1,227,588,192.69, a decrease of 4.02% from ¥1,279,050,151.42 at the end of the previous year[17]. - The net assets attributable to shareholders decreased by 4.35% to ¥963,137,966.32 from ¥1,006,947,231.67 at the end of the previous year[17]. - The basic earnings per share for the first half of 2022 was -¥0.11, compared to -¥0.09 in the same period last year[18]. - The weighted average return on net assets was -4.48%, compared to -3.95% in the same period last year[18]. - The company did not propose any profit distribution plan for the reporting period[5]. - The company reported a revenue of 60,945,385.32 RMB, a decrease of 20.23% compared to the previous year[83]. - The net profit attributable to the parent company was a loss of 44,178,500 RMB, an increase in loss by 5,471,700 RMB year-on-year[83]. - The total comprehensive income for the first half of 2022 was a loss of CNY 46,456,609.51, compared to a loss of CNY 38,296,241.66 in the first half of 2021[168]. Research and Development - Research and development expenses accounted for 84.72% of operating revenue, an increase of 23.60 percentage points from 61.12% in the previous year[18]. - The total R&D investment amounted to ¥51,635,182.73, representing a 10.59% increase compared to ¥46,691,884.08 in the same period last year, with R&D investment accounting for 84.72% of operating revenue, an increase of 23.60 percentage points[54]. - The company has built a research and development system that includes collaboration with universities and hospitals to enhance product innovation[28]. - The company has developed high-precision online calibration technology for surgical robots, achieving an error margin of less than 0.5 mm[37]. - The company has created algorithms for multi-modal medical image fusion, allowing for high-precision integration of preoperative and intraoperative images[38]. - The company employs AI algorithms for automatic feature recognition in medical imaging, achieving an error of less than 1 pixel, thus improving accuracy and reducing operational errors[40]. - The company has developed a modular design technology for surgical tools, enabling the orthopedic surgical robot to perform over ten different surgical procedures, with ongoing expansion of capabilities[45]. - The company has developed a motion safety control technology for the robotic arm, ensuring that the arm operates within a safe range throughout the surgical process[44]. - The company has submitted 30 new patent applications during the reporting period, including 9 invention patent applications, and obtained 35 new patent authorizations, with a total of 373 patent applications and 243 authorizations accumulated as of June 30, 2022[52]. Market Position and Strategy - The company is a leading player in the orthopedic surgical robot industry in China, being the first listed medical robot company on the Shanghai Stock Exchange[23]. - The company has established a diversified revenue structure, including sales of disposable surgical tools and ongoing medical technology service income[27]. - The orthopedic surgical robot industry is expected to continue rapid growth, potentially reaching $33.6 billion by 2026, with a CAGR of 26.2% from 2020[31]. - The company operates a sales model primarily based on distribution, supported by direct sales to medical institutions[26]. - The company is actively expanding its market presence and has introduced a "purchase technology service" model, enhancing its business development efforts[64]. - The company is focusing on market expansion and new product development as part of its strategic initiatives for future growth[169]. - The company is exploring strategic acquisitions to enhance its market position and product offerings[182]. Risks and Challenges - The report includes a risk statement regarding forward-looking statements, indicating potential risks in future plans and strategies[5]. - The company faces significant challenges in new product and technology development due to high technical barriers and long R&D cycles[71]. - The company is at risk of core technology leakage, which could undermine its competitive advantage in the orthopedic surgical robot market[72]. - The company’s existing orthopedic surgical robots may face competition from disruptive treatment methods or superior products in the market[74]. - The company is experiencing intensified market competition from major players like Medtronic and Stryker, which could impact its market share and profitability[75]. - Regulatory changes in China could affect the company’s product registration and operational licenses, posing risks to its business[81]. Financial Management and Governance - The company has received approval for its refinancing plan, which will provide strong financial support for its ongoing development and enhance its competitive edge[69]. - The company has not yet achieved profitability, which may adversely affect shareholder returns in the short term[70]. - The company has committed to not transferring or entrusting the management of shares held before the IPO for 36 months from the listing date, which is July 29, 2019[108]. - The company will not reduce its holdings of pre-IPO shares for three complete accounting years after the IPO, and can only reduce up to 2% of total shares in the fourth and fifth accounting years[109]. - The company has established a clear framework for share reduction and transfer post-IPO to maintain investor confidence[111]. - The company has committed to enhancing the management of raised funds to mitigate usage risks and accelerate investment progress in projects[120]. - The company will implement a cash dividend policy to strengthen investor return mechanisms[120]. - The company guarantees that there are no fraudulent issuance circumstances related to the public offering of stocks[120]. - The company will publicly explain any unfulfilled commitments and apologize to shareholders and the public if it fails to meet its obligations[124]. Subsidiaries and Ownership - The company has a 100% ownership in its subsidiaries, indicating full control over their operations and financial performance[98]. - The consolidated financial statements include four subsidiaries: Beijing Tianzhihang Medical Technology Service Co., Ltd., Beijing Shuimu Dongfang Medical Robot Technology Innovation Center Co., Ltd., Anhui Tianzhihang Medical Technology Co., Ltd., and TINAVI (Hong Kong) Holding Limited[200]. - The company has a total of 300,000 shares held by foreign natural persons, which is 0.0% of the total[141]. - The top shareholder, Zhang Songgen, holds 75,664,000 shares, representing 18.02% of the total shares[146]. - The second-largest shareholder, Beijing Zhihui Hechuang Investment Partnership, holds 33,045,560 shares, accounting for 7.87%[146]. Legal and Compliance - There were no major lawsuits or arbitration matters reported during the reporting period, reflecting a stable legal standing[128]. - The company has not faced any environmental penalties or pollution incidents during the reporting period[105]. - There were no violations or penalties reported against the company or its executives during the reporting period, indicating compliance with regulations[128]. - The company has pledged to adhere to all relevant regulations set forth by the China Securities Regulatory Commission[126].